Implantable cardioverter-defibrillators (ICD) can terminate ventricular tachy-arrhythmias (VTs) with shocks or antitachycardia pacing (ATP). Lots of studies demonstrated that ATP terminates most of VTs but with a 1% to 7% risk of acceleration or precipitation of these arrhythmias. Also, anti-bradycardia therapy can have an intrinsic arrythmogenic risk.
Mauro Toniolo, Elisabetta Daleffe, Luca Rebellato, Domenico Facchin and Alessandro Proclemer
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2018 All rights reserved. iMedPub Last revised : March 17, 2018